Healthy men to help unravel how new kidney drug is processed
NCT ID NCT07463053
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial will enroll 8 healthy Chinese men to study how the experimental drug JMKX003142 is absorbed, broken down, and eliminated from the body. Participants will receive the drug in both pill and IV forms, some with a radioactive tracer. The study aims to measure the drug's bioavailability and how much is excreted in urine and stool. No treatment benefit is expected, as this is purely a research study to guide future dosing in patients with polycystic kidney disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JMKX003142 (a drug being developed for polycystic kidney disease)
- What this could lead to
- If successful, this study will help determine the right dose and how the drug is cleared from the body, supporting future trials in patients with polycystic kidney disease.
- What could go wrong
- This is a very early, small study in healthy volunteers, not patients. It is designed to gather basic information, not to test if the drug works. The drug may still fail in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADPKD (AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.